You are here

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B

Last updated on March 24, 2020

FOR MORE INFORMATION
Study Location
University Multiprofile Hospital for Active Treatment ''Georgi Stranski'' EAD
Pleven, , 5800 Bulgaria
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hemophilia A, Hemophilia B
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12-74 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Participants with a diagnosis of severe hemophilia A or B

- Participant or legally authorized representative, or participant's caregiver capable
of giving signed informed consent (or minor assent, when applicable).

Participants who are enrolled into the Non-Inhibitor Cohort must also meet the following
criteria:

- No detectable or documented history of inhibitors

- Participants outside the US and Canada with FVIII/FIX replacement, and willing to
continue to receive routine prophylaxis treatment with FVIII/FIX replacement during
the Observational Phase. Participants in the US and Canada receiving routine
prophylaxis treatment not eligible to be enrolled.

- Participants with on-demand treatment regimen with ≥6 acute bleeding episodes
(spontaneous and/or traumatic) that required coagulation factor infusion during the 6
months period prior to Screening and willing to continue to receive on demand
treatment during the Observational Phase.

- Participants who have documented inhibitors while on factor-replacement therapy but
who do not meet the quantitative inhibitor criteria described in the prior bullet at
the time of Screening (eg, participant with a previously documented high-titer
inhibitor (≥5 BU/mL) and whose condition precludes re-challenge with FVIII or FIX
replacement) may be considered for eligibility on a case-by-case basis with prior
approval from the Pfizer Medical Monitor.

Participants who are enrolled into the Inhibitor Cohort must also meet the following
criteria:

- Documentation of current high titer inhibitor (≥5 BU/mL) or current low titer
inhibitor ( recovery Phase

- Participants with on-demand treatment regimen with ≥6 bleeding episodes (spontaneous
and/or traumatic) necessitating treatment with bypass factor for at least 6 months
prior to screening and willing to continue to receive on-demand treatment during the
Observational Phase.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Previous or current treatment for and/or history of coronary artery diseases, venous
or arterial thrombosis or ischemic disease

- Known planned surgical procedure during the planned study period.

- Known hemostatic defect other than hemophilia A or B.

- Abnormal renal or hepatic function

- Current unstable liver or biliary disease

- Abnormal hematologic parameters

- Abnormal coagulation activity

- Other acute or chronic medical or psychiatric condition or laboratory abnormality that
may increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator,

- Current routine prophylaxis with bypassing agent or non-coagulation non-factor-
replacement therapy

- Regular, concomitant therapy with immunomodulatory drugs

- Ongoing or planned use of immune tolerance induction or prophylaxis with FVIII or FIX
replacement during the Active Treatment Phase.

- Previous exposure to PF 06741086 during to participation in studies B7841002 and
B7841003.

- Participation in other studies involving investigational drug(s) within 30 days (or as
determined by local requirements) or 5 half-lives prior to study entry and/or during
study participation.

- CD4 cell count ?200/uL if human immunodeficiency virus (HIV)-positive

- Clinically relevant ECG abnormalities that may affect participant safety or
interpretation of study results.

- Individuals with hypersensitivity or an allergic reaction to hamster protein or other
components of the study intervention.

- Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
participants who are Pfizer employees, including their family members, directly
involved in the conduct of the study.

NCT03938792
Pfizer
Recruiting
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B
Official Title  ICMJE AN OPEN-LABEL STUDY IN ADOLESCENT AND ADULT SEVERE (COAGULATION FACTOR ACTIVITY <1%) HEMOPHILIA A OR B PATIENTS WITH OR WITHOUT INHIBITORS COMPARING STANDARD TREATMENT TO PF-06741086 PROPHYLAXIS
Brief Summary Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC) administration provides for treatment options in the absence of reliable vascular access, increased convenience and may enable better compliance. Combined, these qualities should result in a reduction of bleeding episodes.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Intervention Model: Crossover Assignment
Intervention Model Description:
This is a one way Cross-Over Prevention study with 1 Arm that has No masking.

Masking: None (Open Label)
Primary Purpose: Treatment

Condition  ICMJE
  • Hemophilia A
  • Hemophilia B
Intervention  ICMJE Drug: PF-06741086
300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
Study Arms  ICMJE Experimental: PF-06741086
Participants will be assigned to treatment with PF-06741086 after a 6 month Observation Phase on their current hemophilia regimen.
Intervention: Drug: PF-06741086
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 2, 2019)
145
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 27, 2023
Estimated Primary Completion Date April 27, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  • Participants with a diagnosis of severe hemophilia A or B
  • Participant or legally authorized representative, or participant's caregiver capable of giving signed informed consent (or minor assent, when applicable).

Participants who are enrolled into the Non-Inhibitor Cohort must also meet the following criteria:

  • No detectable or documented history of inhibitors
  • Participants outside the US and Canada with FVIII/FIX replacement, and willing to continue to receive routine prophylaxis treatment with FVIII/FIX replacement during the Observational Phase. Participants in the US and Canada receiving routine prophylaxis treatment not eligible to be enrolled.
  • Participants with on-demand treatment regimen with ?6 acute bleeding episodes (spontaneous and/or traumatic) that required coagulation factor infusion during the 6 months period prior to Screening and willing to continue to receive on demand treatment during the Observational Phase.
  • Participants who have documented inhibitors while on factor-replacement therapy but who do not meet the quantitative inhibitor criteria described in the prior bullet at the time of Screening (eg, participant with a previously documented high-titer inhibitor (?5 BU/mL) and whose condition precludes re-challenge with FVIII or FIX replacement) may be considered for eligibility on a case-by-case basis with prior approval from the Pfizer Medical Monitor.

Participants who are enrolled into the Inhibitor Cohort must also meet the following criteria:

  • Documentation of current high titer inhibitor (?5 BU/mL) or current low titer inhibitor (<5 BU/mL) refractory to FVIII or FIX replacement and with FVIII or FIX recovery <60% of expected within previous 30 days prior to Baseline of Observational Phase
  • Participants with on-demand treatment regimen with ?6 bleeding episodes (spontaneous and/or traumatic) necessitating treatment with bypass factor for at least 6 months prior to screening and willing to continue to receive on-demand treatment during the Observational Phase.

Exclusion Criteria

  • Previous or current treatment for and/or history of coronary artery diseases, venous or arterial thrombosis or ischemic disease
  • Known planned surgical procedure during the planned study period.
  • Known hemostatic defect other than hemophilia A or B.
  • Abnormal renal or hepatic function
  • Current unstable liver or biliary disease
  • Abnormal hematologic parameters
  • Abnormal coagulation activity
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator,
  • Current routine prophylaxis with bypassing agent or non-coagulation non-factor- replacement therapy
  • Regular, concomitant therapy with immunomodulatory drugs
  • Ongoing or planned use of immune tolerance induction or prophylaxis with FVIII or FIX replacement during the Active Treatment Phase.
  • Previous exposure to PF 06741086 during to participation in studies B7841002 and B7841003.
  • Participation in other studies involving investigational drug(s) within 30 days (or as determined by local requirements) or 5 half-lives prior to study entry and/or during study participation.
  • CD4 cell count ?200/uL if human immunodeficiency virus (HIV)-positive
  • Clinically relevant ECG abnormalities that may affect participant safety or interpretation of study results.
  • Individuals with hypersensitivity or an allergic reaction to hamster protein or other components of the study intervention.
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Pfizer employees, including their family members, directly involved in the conduct of the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
Ages  ICMJE 12 Years to 74 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Listed Location Countries  ICMJE Bulgaria,   Korea, Republic of,   Turkey,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03938792
Other Study ID Numbers  ICMJE B7841005
2018-003660-31 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/da....
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/da...
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date March 2020

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now